Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research (TWINCORE), Hannover, Germany.
J Immunol Res. 2017;2017:7232361. doi: 10.1155/2017/7232361. Epub 2017 Feb 1.
The human interferon (IFN) response is a key innate immune mechanism to fight virus infection. IFNs are host-encoded secreted proteins, which induce IFN-stimulated genes (ISGs) with antiviral properties. Among the three classes of IFNs, type III IFNs, also called IFN lambdas (IFNLs), are an essential component of the innate immune response to hepatitis C virus (HCV). In particular, human polymorphisms in IFNL gene loci correlate with hepatitis C disease progression and with treatment response. To date, the underlying mechanisms remain mostly elusive; however it seems clear that viral infection of the liver induces IFNL responses. As IFNL receptors show a more restricted tissue expression than receptors for other classes of IFNs, IFNL treatment has reduced side effects compared to the classical type I IFN treatment. In HCV therapy, however, IFNL will likely not play an important role as highly effective direct acting antivirals (DAA) exist. Here, we will review our current knowledge on IFNL gene expression, protein properties, signaling, ISG induction, and its implications on HCV infection and treatment. Finally, we will discuss the lessons learnt from the HCV and IFNL field for virus infections beyond hepatitis C.
人类干扰素 (IFN) 反应是抵抗病毒感染的关键固有免疫机制。IFNs 是宿主编码的分泌蛋白,可诱导具有抗病毒特性的 IFN 刺激基因 (ISGs)。在三类 IFN 中,III 型 IFN,也称为 IFN 拉姆达 (IFNLs),是对丙型肝炎病毒 (HCV) 固有免疫反应的重要组成部分。特别是,IFNL 基因座的人类多态性与丙型肝炎疾病进展和治疗反应相关。迄今为止,其潜在机制仍大多难以捉摸;然而,似乎很明显,病毒感染肝脏会诱导 IFNL 反应。由于 IFNL 受体的组织表达比其他类 IFN 的受体更受限制,因此与经典的 I 型 IFN 治疗相比,IFNL 治疗的副作用较小。然而,在 HCV 治疗中,IFNL 可能不会发挥重要作用,因为存在高效的直接作用抗病毒药物 (DAA)。在这里,我们将回顾我们目前对 IFNL 基因表达、蛋白特性、信号转导、ISG 诱导及其对 HCV 感染和治疗的影响的了解。最后,我们将讨论从 HCV 和 IFNL 领域获得的关于丙型肝炎以外病毒感染的经验教训。